Castle Biosciences ( (CSTL) ) has released its Q3 earnings. Here is a breakdown of the information Castle Biosciences presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Castle Biosciences, a leading diagnostics company in the dermatologic and gastroenterological sectors, is known for its innovative tests that guide patient care.
In its third quarter of 2025, Castle Biosciences reported strong financial performance with a revenue of $83 million and a significant increase in test report volumes, despite facing challenges from coverage determinations and product discontinuations.
The company saw a 67% increase in non-dermatologic revenue compared to the previous year, and a 36% rise in total test reports for its core revenue drivers, DecisionDx-Melanoma and TissueCypher. However, the company experienced a net loss of $0.5 million, influenced by non-cash stock-based compensation expenses, and a decrease in adjusted EBITDA from $21.6 million in the previous year to $9.2 million.
Looking forward, Castle Biosciences has raised its full-year 2025 revenue guidance to $327-335 million, reflecting confidence in its strategic initiatives and the launch of new products like AdvanceAD-Tx, aimed at addressing unmet needs in clinical dermatology.
Trending Articles:
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package